Antibody library screening is widely used to identify antibody fragments, such as scFv, Fab, and single-domain antibodies, from large molecular repertoires. Compared with immunization-dependent approaches, library screening can be especially useful for challenging...
China's National Medical Products Administration (NMPA) approved satricabtagene autoleucel (satri-cel) on 22 June 2026, making it the world's first CAR-T cell therapy approved for a solid tumour. Developed by Shanghai-based CARsgen Therapeutics, satri-cel is cleared...
The repair and replacement of bone is a major clinical problem. The need for efficient treatments of spinal injuries, has become increasingly common and remains a significant challenge in the field of orthopedics. Regenerative medicine in bone repair is the use of...
CRISPR gene editing in 2026 is no longer a technology to watch. It is a technology delivering results. Across three distinct disease areas, rare inherited conditions, haematologic and solid cancers, and autoimmune disease, clinical programmes are accumulating...
The biotech IPO surge has turned 2026 into a comeback year, and one statistic captures it: in the first six months, biopharma companies raised more from initial public offerings than the entire sector managed across the whole of 2025. After a punishing multi-year...
It seems that artificial intelligence is being proposed as an answer to what could be considered as one of the most serious problems facing the life sciences sector – the problem of information overload. There has never been as much data, documentation, literature,...
It seems that artificial intelligence is being proposed as an answer to what could be considered as one of the most serious problems facing the life sciences sector – the problem of information overload. There has never been as much data, documentation, literature,...
Oncolytic virus development is gaining increasing attention in cancer immunotherapy research because of its ability to combine direct tumor cell killing with immune activation. Unlike conventional therapeutic strategies that focus on one pathway or one target,...
Radiation therapy is one of the important tools in the fight against cancer. About 50% of all cancer patients receive radiation therapy. Few modalities have had the same lasting impact across such a broad range of tumor types. In central nervous system (CNS) oncology,...
There are FDA-approved therapies on the market today that can permanently resolve a disease in a single administration, for a price of one to three million dollars. The reimbursement system responsible for covering that cost was built around medications that people...
A record year of out-licensing pulled the West's early pipeline sourcing toward Shanghai and Suzhou. The discount that started it is already being competed away. What outlasts it is a two-source model for global pharma innovation. For most of the past decade, a...
When Kailera Therapeutics priced its initial public offering on 16 April 2026, it did more than raise money. The Kailera Therapeutics IPO set a new benchmark for an industry that had spent the better part of three years in the wilderness. Priced at $625 million, it...
Biotech has never lacked scientific innovation. What the industry continues to underestimate is how difficult it is to turn promising science into an actual therapy that reaches patients. Over the last several years, I have seen strong assets struggle for reasons...
When López-Otín and colleagues published “The Hallmarks of Aging” in Cell in 2013, they did something the field of biogerontology had quietly needed for decades: they created a framework. Nine interconnected processes, from genomic instability and telomere attrition...
The biotech M&A 2026 market has entered what many analysts are already calling a breakout year. In the first four months of 2026 alone, pharma and biotech companies have signed deals worth approximately $84 billion, and the pipeline of transactions shows no sign...
Thesis Early-stage life science development is increasingly constrained not by lack of data, but by fragmented, multi-scale evidence that resists straightforward interpretation. AI systems can assist in structuring this complexity – through literature triage,...
In the high-stakes world of drug discovery and biomanufacturing, the spotlight typically shines on breakthrough modalities, venture rounds, and FDA milestones. Yet, behind every clinical success is a physical environment that either accelerated the science or quietly...
In fast-moving areas like radiopharmaceuticals and precision immunology, the biggest portfolio risk is often not uncertainty itself, but false certainty created by mismatched benchmarks. As life sciences enters a more disciplined cycle, one pattern shows up across...